You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: Hillhurst Biopharmaceuticals, Inc. Topic: NIAID
PROJECT SUMMARY There is an urgent need for the development of new approaches to treat patients suffering from pulmonary injury from viral infections, as demonstrated by the severe impact of COVID-19, which is a global pandemic that, at the time of writing, is estimated have impacted approximately 50 million people in the United States, leading to morbidity, substantial hospital and intensive care ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: SCALED MICROBIOMICS LLC Topic: NIAID
Project Summary/Abstract for STTR Phase I Application: An immunotherapeutic IgY formulation against norovirus diarrhea Human norovirus (HuNoV) infects millions of people globally each year, causing diarrheal illness resulting in more than 200,000 deaths annually, particularly in the very young, the very old, and the immunocompromised. There is currently neither an effective vaccine nor effective t ...STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
SBC: MYOFINITY BIOSCIENCES INC Topic: NIAMS
PROJECT ABSTRACT The goal of this Phase I STTR project is to accomplish key milestones in commercializing a novel SaCas9 nickase-based system (CRD-002) to treat dystrophinopathies in order to restore the production of healthy, endogenous full-length dystrophin protein otherwise compromised by duplication mutations. Duchenne muscular dystrophy (DMD) is characterized by progressive muscle loss and c ...STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
SBC: CODOMAX INC. Topic: NCATS
Abstract – Codomax has developed a codon engineering platform that enables bespoke, high-yield, cost- effective protein manufacturing by leveraging a newly discovered translational regulatory system in industrially relevant cell systems. Protein manufacturing has a current estimated market size of over $300 billion, distributed among the areas of antibodies and biologic therapeutics, biotechnolo ...STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
Light-directed therapy of squamous cell head and neck cancer with a novel dual-acting chemotherapeutic.SBC: LIGHT SWITCH BIO, LLC Topic: 102
PROJECT SUMMARY. In this Phase I STTR project, Light Switch Bio will collaborate with Virginia Commonwealth University and the University of Pennsylvania for the early-stage development of IR-Platin, a first-in-class photoactivated chemotherapy for treatment of head and neck squamous cell carcinoma (HNSCC), the sixth leading cancer worldwide. Most patients with HNSCC present with advanced disease ...STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
SBC: RIPPLE LLC Topic: NIDCD
Project Summary and Abstract The most common neurogenic voice disorder is unilateral vocal fold paralysis (UVFP), which can substantially reduce quality of life. Current available surgical treatments offer only temporary improvement in voice through placement of resorbable materials or involve permanent, invasive alteration of the larynx that incompletely restores voice and often requires revision ...STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
SBC: HEMATHERIX LLC Topic: NHLBI
Project Summary/Abstract Hematherix is developing superFVa for the treatment of acute traumatic coagulopathy (ATC). Mortality rates with traumatic hemorrhage often exceed 40%, exposing an unmet clinical need for targeted drug development. ATC develops early on as the consequence of severe trauma and shock, prior to additional iatrogenic effects. ATC is distinct from other coagulopathies and is cha ...STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
SBC: DARE BIOSCIENCE, INC. Topic: NICHD
In the United States, one in ten babies is born prematurely. The earlier in pregnancy a baby is born, the more likely they will have an extended hospital stay, as well as serious health complications such as respiratory distress syndrome, necrotizing enterocolitis, deafness, vision problems and cerebral palsy. Maternal stress is a well-established risk factor for preterm birth, and recent studies ...STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
SBC: VOX BIOMEDICAL LLC Topic: NIDA
Project Summary We have conducted a pilot study using some of the elements in the present proposal that provide support for the notion that a well selected set of psychomotor/performance tasks can be used to predict driving impairment via a simulated program. Adding these two approaches to the existing STTR project will add significantly to the value of the data focused on developing a breath test ...STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: TENDEL THERAPIES INC Topic: NIAID
This project will establish proof-of-concept for CCR5 immunotoxins as HIV reservoir-depletion agents for use in cure strategies. HIV cure and remission strategies require elimination or reduction of the HIV reservoir. Approaches to reservoir reduction pursued by other groups include gene editing, i.e., direct removal of integrated provirus; latency reversal and an accompanying “kill” strategy; ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health